A phase 1 clinical trial (NCT03608631) for treating metastatic pancreatic cancer patients with KRAS G12D mutation with MSC-derived exosomes containing KRAS G12D siRNA (iExosomes) is ongoing. The gene discussed is KRAS; the disease is pancreatic neoplasm.